Alumis (NASDAQ:ALMS) Price Target Raised to $55.00

Alumis (NASDAQ:ALMS) had its target price raised by Oppenheimer from $50.00 to $55.00 in a research report released on Monday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

ALMS has been the topic of several other reports. Leerink Partners upped their target price on shares of Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. Wells Fargo & Company boosted their price target on Alumis from $17.00 to $39.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a report on Monday, December 29th. Stifel Nicolaus began coverage on Alumis in a research note on Wednesday, February 25th. They issued a “buy” rating and a $44.00 price objective for the company. Finally, Raymond James Financial started coverage on Alumis in a report on Tuesday, March 10th. They set a “strong-buy” rating and a $46.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Alumis has an average rating of “Moderate Buy” and an average target price of $38.60.

Alumis Stock Performance

Alumis stock opened at $22.73 on Monday. The company has a market cap of $2.89 billion, a P/E ratio of -7.43 and a beta of -0.61. Alumis has a one year low of $2.76 and a one year high of $30.60. The business has a fifty day moving average of $26.34 and a two-hundred day moving average of $14.85.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The company had revenue of $1.93 million for the quarter, compared to analyst estimates of $2.75 million. Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%. Sell-side analysts predict that Alumis will post -8.51 EPS for the current year.

Insider Activity

In other news, major shareholder Foresite Labs, Llc bought 411,764 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the transaction, the insider owned 5,702,536 shares in the company, valued at $96,943,112. The trade was a 7.78% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Foresite Capital Management Vi bought 411,764 shares of the stock in a transaction on Thursday, January 8th. The stock was purchased at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the purchase, the insider directly owned 5,702,536 shares in the company, valued at $96,943,112. This trade represents a 7.78% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 1,823,527 shares of company stock worth $30,999,959. 40.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alumis

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in Alumis in the fourth quarter valued at $491,000. Invesco Ltd. lifted its position in Alumis by 225.6% during the fourth quarter. Invesco Ltd. now owns 421,819 shares of the company’s stock worth $4,117,000 after buying an additional 292,250 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in Alumis in the 4th quarter worth about $146,000. Virtus Investment Advisers LLC purchased a new stake in Alumis in the 4th quarter valued at about $226,000. Finally, Wellington Management Group LLP grew its holdings in Alumis by 2.2% in the 4th quarter. Wellington Management Group LLP now owns 169,093 shares of the company’s stock valued at $1,650,000 after buying an additional 3,590 shares during the period.

Key Stories Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright raised EPS estimates across Q1–Q4 and lifted FY2026/FY2027 outlooks (e.g., FY2026 from ($2.99) to ($2.89); Q1–Q4 tweaks), while maintaining a “Buy” rating and a $25 price target — this reduces projected losses and provides an analyst-backed upside case. HC Wainwright research coverage (summary)
• Positive Sentiment: Chardan Capital assigned a Buy rating, adding an additional institutional endorsement that can attract buyer interest. Alumis Earns Buy Rating from Chardan Capital
• Positive Sentiment: An Oppenheimer analyst is reported to expect the stock to rise, reinforcing bullish sentiment from multiple brokers and likely supporting demand. Oppenheimer bullish note
• Neutral Sentiment: General market coverage (CNN) lists ALMS among tracked stocks; broad news distribution can increase visibility but doesn’t by itself change fundamentals. CNN: Alumis Inc.
• Neutral Sentiment: A news piece with a contrary headline referencing a “pessimistic forecast” appeared, but the underlying broker actions (above) show upward revisions and Buy ratings — treat the conflicting headlines cautiously. HC Wainwright pessimistic forecast article

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.